



Universiteit
Leiden
The Netherlands

Keyhole limpet hemocyanin challenge model for studying adaptive immune system responses in early-phase clinical drug development

Saghari, M.

Citation

Saghari, M. (2024, December 17). *Keyhole limpet hemocyanin challenge model for studying adaptive immune system responses in early-phase clinical drug development*. Retrieved from <https://hdl.handle.net/1887/4172487>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4172487>

Note: To cite this publication please use the final published version (if applicable).

**KEYHOLE LIMPET HEMOCYANIN CHALLENGE MODEL FOR STUDYING
ADAPTIVE IMMUNE SYSTEM RESPONSES IN EARLY-PHASE CLINICAL DRUG DEVELOPMENT**

For Mira Eflin, my beacon of light

**KEYHOLE LIMPET HEMOCYANIN
CHALLENGE MODEL FOR STUDYING
ADAPTIVE IMMUNE SYSTEM
RESPONSES IN EARLY-PHASE
CLINICAL DRUG DEVELOPMENT**

Proefschrift

© Mahdi Saghari, 2024

DESIGN Caroline de Lint, Den Haag (caro@delint.nl)

COVER IMAGE *Megathura crenulata*, © Andrew Harmer, 2016

Protection of Megathura crenulata and its habitat is of vital importance, especially since keyhole limpet hemocyanin cannot be produced synthetically.

Publication of this thesis was financially supported by the Centre for Human Drug Research (CHDR) foundation in Leiden, the Netherlands

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof. dr. ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 17 december 2024
klokke 10:00 uur

door
Mahdi Saghari
geboren te Herat, Afghanistan
in 1989

PROMOTORES

Prof. dr. J. Burggraaf
Prof. dr. R. Rissmann

COPROMOTOR

Dr. M. Moerland

PROMOTIECOMMISSIE

Prof. dr. R. van Doorn
Prof. dr. M.H.M. Heemskerk
Prof. dr. E.P. Prens (*Erasmus Medisch Centrum, Rotterdam*)
Dr. B.A. Slütter (*Leiden Academic Centre for Drug Research, Leiden*)

CHAPTER I General introduction – 7

SECTION I KLH IMMUNE CHALLENGE MODEL BACKGROUND

CHAPTER II Characterization of KLH-driven immune responses in clinical studies: a systematic review – 21

SECTION II KLH IMMUNE CHALLENGE MODEL IN HEALTHY VOLUNTEERS

CHAPTER III A randomized controlled trial with a delayed-type hypersensitivity model using keyhole limpet hemocyanin to evaluate adaptive immune responses in man – 57

SECTION III KLH IMMUNE CHALLENGE MODEL IN EARLY-PHASE CLINICAL TRIALS

CHAPTER IV OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005 – 79

CHAPTER V Impact of oral administration of single-strain *Lactococcus lactis* spp. *cremoris* on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: a randomized placebo-controlled trial in healthy volunteers – 101

CHAPTER VI Evaluation of single-strain *Prevotella histicola* on KLH-driven immune responses in healthy volunteers: a randomized controlled trial with EDP1815 – 125

CHAPTER VII Clinical translation of anti-inflammatory effects of *Prevotella histicola* in Th1, Th2, and Th17 inflammation – 147

CHAPTER VIII Summary and general discussion – 175

CHAPTER IX Nederlandse samenvatting – 189

APPENDICES

Curriculum Vitae – 203

List of publications – 205

Acknowledgements – 208